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Abstract MicroRNAs (miRNAs) are small regulatory
molecules that negatively regulate gene expression by
base-pairing with their target mRNAs. miRNAs have
contribute significantly to cancer biology and recent studies
have demonstrated the oncogenic or tumor-suppressing
role in cancer cells. In many tumors up-regulation miRNAs
has been reported especially miR-222 has been shown to be
up-regulated in B chronic lymphocytic leukemia (B-CLL).
In this study we assessed the effected inhibition of miR-
222 in cell viability of B-CLL. We performed inhibition of
mir-222 in B-CLL cell line (183-E95) using locked nucleic
acid (LNA) antagomir. At different time points after LNA-
anti-mir-222 transfection, miR-222 quantitation and cell
viability were assessed by qRT-real time polymerase chain
reaction and MTT assays. The data were analyzed by
independent t test and one way ANOVA. Down-regulation
of miR-222 in B-CLL cell line (183-E95) with LNA
antagomir decreased cell viability in B-CLL. Cell viability
gradually decreased over time as the viability of LNA-anti-
mir transfected cells was\47 % of untreated cells at 72 h
post-transfection. The difference in cell viability between
LNA-anti-miR and control groups was statistically signif-
icant (p\ 0.042). Based on our findings, the inhibition of
miR-222 speculate represent a potential novel therapeutic
approach for treatment of B-CLL.
Keywords MicroRNA  miR-222  Chronic lymphocytic
leukemia  Locked nucleic acid
Introduction
MiRNAs are a family of 19-25-nucleotide small RNAs
that negatively regulate gene expression at the post-tran-
scriptional level by binding to the 30-untranslated region
of target mRNA [1, 2]. miRNAs play essential roles in
many normal biological processes involving cell prolif-
eration, differentiation, growth and development, meta-
bolism, aging and apoptosis [3–7]. Recently, the role of
microRNAs (miRNAs) in cancer has received much
attention, much evidences points to miRNAs functioning
as tumor promoters (oncomirs) such as: miR-155 and
miR-17–92 [8], or tumor suppressors (anti-oncomirs) such
as: miR-15a, miR-16, and miRNAs of the miR-34 and let-
7 families [8, 9]. miRNA alterations are effective on all
six hallmarks of malignant cells; in CLL, the main effects
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are apoptosis, evasion, self-sufficiency in growth, and as
recently found, stimulation of dissemination and angio-
genesis [10].
Chronic lymphocytic leukemia (CLL) is a disease of
older patients, and with most patients C65 years of age
and having at least one major property [11, 12], CLL is of
B cell origin, it occurs in two forms, indolent and
aggressive [11]. The most frequency chromosomal
abnormalities detected in CLL include deletion at 13q
(55 %), 11q (18 %), trisomy 12 (12–16 %) and 17p (8 %)
but molecular details still under investigation [13, 14].
MicroRNAs in CLL can function as oncogenes, tumor
suppressors, or be used as markers for disease onset/
progression for example, in indolent CLL, 13q14 dele-
tions targeting miR-15/16 initiate the disease, while in
aggressive CLL miR-181 targets the critical TCL1
oncogene [11, 15]. The relative expression levels of cer-
tain microRNAs correlate with prognostic indicators in
CLL for example, leukemia-cell expression of zeta-asso-
ciated protein of 70 kDa (ZAP-70), use of unmutated
immunoglobulin heavy-chain variable region genes
(IGHV) [16–19]. miR-221/222 are highly homologous
miRNAs encoded in tandem on the X chromosome,
Amplification or overexpression of miR-221/222 is
reported in hematopoietic malignancies indicating that
miR-221/222 could be potential therapeutic targets [20].
The direct association between miR-222 and B-cell
malignancies is indicated, upregulation of human miR-
222 was reported in aggressive forms of CLL, glioblas-
toma, and thyroid papillary carcinoma [20–22]. The miR-
221/222 cluster is capable of modulating the expression of
p27 gene, it is a regulatory loop that contributes to
keeping CLL cells in resting condition [20].
In this study, we knockdown mir-222 by locked nucleic
acid (LNA), then evaluation expression of mir-222 and cell
viability in 183-E95 cell line at 24,48,72 h after inhibtion.
Materials and Methods
Cell Culture
The 183-E95 cell line was purchased from the National
Cell Bank of Iran (NCBI; Pasteur Institute, Iran).The cell
culture was maintained in Roswell Park Memorial Institute
(RPMI) 1640 (Gibco, Paisley, UK) supplemented with fetal
calf serum (FCS; Gibco, Paisley, UK) 15 % v/v, 100 U/mL
of penicillin and 100 lg/mL of streptomycin (Gibco,
Paisley, UK) in a humid and air-saturated atmosphere
consisting of 5 % CO2 inside 25-cm
2 culture flasks (Nunc,
Roskilde, Denmark) at 37 C. The cells were passaged
twice a week to keep an exponential growth phase.
Cell Transfection
The nucleotide sequences of miR-222 were obtained from
www.mirbase.org as GAG ACC CAG TAG CCA GAT
GTA GCT. The miRCURY LNA microRNA InhibitorTM
for hsa-miR-222 and miRNA inhibitor negative control
(scrambled) oligonucleotides were purchased from Exiqon,
Denmark. Both oligonucleotides were labeled at the 50 end
with fluorescent dyes, 6-FAM, for subsequent detection of
transfected cells.
183-E95 cell transfection was performed by the Lipo-
fectamin RNAiMax transfection Reagent (Invitrogen Ger-
many) according to the manufacturer instructions. Briefly,
5 9 105 cells in the exponential growth phase were cul-
tured in six-well culture plates (Nunc, Roskilde, Denmark)
containing 1.8 mL RPMI 1640 per well without antibiotics
and FCS. The 30 pmol mercury locked nucleic acids
(LNA) microRNA inhibitorTM was mixed with 5 lL
Lipofectamin RNAiMax Transfection ReagentTM in 200 ll
Opti-MEMI MediumTM (Gibco, Paisley, UK) and incu-
bated for 15 min at room temperature. Then, the complex
was added to the cells and swirled carefully for even dis-
tribution over the entire plate surface. After 8-h incubation,
the FCS and antibiotics were added, and the cells were
incubated for 24, 48, and 72 h. Untreated and scrambled-
LNA transfected cells were cultured parallel to the
LNAanti-miR transfected cells. Efficiency of the transfec-
tion was investigated by flow cytometry and fluorescent
microscopy. LNA was conjugated with 6 FAMTM Fluo-
rescein (6-carboxyfluorescein) to identify and quantify
LNA transfected cells by fluorescent microscopy and
FACSCalibur flow cytometer (Partec, Germany).
Reverse Transcriptase micRNA Real Time
Polymerase Chain Reaction (PCR)
First the expression level of mir-222 in B-CLL cell line
(183-E95) was determined by qRT-real time PCR. Reverse
transcriptase (RT) miRNA real time PCR was done to
determine the efficiency of miR-222 inhibition using LNA
anti-miR. Briefly, the total cellular RNA was extracted 24,
48, and 72 h post-transfection with the miRCURY RNA
Isolation KitTM (Genall) and cDNA was synthesized with
the Universal cDNA Synthesis KitTM (Parsgengan). Real
time PCR was performed by SYBR Green Master Mix
KitTM (Takara) and specific miR-222 primers (all con-
sumables in this section were from Metabion, Germany).
Synthetic RNA Snord 47 templates and their primers
(Metabion, Germany) were used for real time PCR internal
control. The ABI Step One Plus (ABI, USA) instrument
was used for real time PCR experiments and the 2-DDCt
method for data calculation.
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Cells Viability Assay
The viability of cells was determined by the MTT (3-[4,
5dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide)
assay, based on reduction of MTT by the mitochondrial
dehydrogenase of intact cells to purple formazan products.
The conversion is directly related to the number of living
cells. The MTT assay was performed at the intervals of 24,
48, and 72 h post-transfection. Two hundred ll of MTT
(Sigma-Aldrich, USA) at the concentration of 50 mg/mL
was added to 5 9 105 183-E95 cells suspended in 2 mL of
RPMI 1640 medium and incubated for 4 h at 37 C in the
darkness. Two hundred ll of dimethyl sulfoxide (Sigma-
Aldrich, USA) was added to each well and was shaken
until dissolution of crystals. Blank samples were prepared
per exactly the same procedure except for cell incorpora-
tion. Absorbance was measured by a spectrophotometer at
570 nm. Reading was converted to the percentage of the
controls.
Statistical Analysis
Statistical analyses were performed using SPSS version
16.0. independent t test and one-way ANOVA was used for
the analysis of the differences between groups. A p value of
\0.05 was considered statistically significant. All experi-
ments were replicated three times.
Results
miRCURY LNA microRNA InhibitorTM powerfully
Inhibits expreation of miR-222
The up-regulation of miR-222 was showed in B-CLL cell
line (183-E95) by qRT-real time PCR. For inhibition of
miR-222, the miRCURY LNA microRNA InhibitorTM was
transfected to 183-E95 cells with the Lipofectamin
RNAiMax Transfection Reagent. On the basis of the initial
optimization experiments, transfection was performed with
30 pM of LNA-anti-miR and 5 ll of the transfection
reagent. As the transfected oligonucleotides were fluo-
rochrome-conjugated, transfection efficiencies were asses-
sed by fluorescence microscopy and flow cytometry.
Carefully optimized protocol produced transfection effi-
ciency of 80 % (Fig. 1).
Expression of miR-222 was assessed by reverse tran-
scriptase microRNA real time PCR in 183-E95 cells
transfected with the miRCURY LNA microRNA Inhibi-
torTM (LNA-anti-miR group); the microRNA inhibitor
scrambled oligonucleotides (scrambled LNA group) and
untreated 183-E95 cells (untreated groups) at 24, 48, and
72 h post-transfection. Although miR-222 expression was a
little lower in the scrambled LNA-transfected cells com-
pared to the untreated cells, the differences were not sta-
tistically significant. However, in all three intervals, the
expression of miR-222 was considerably lower in the
LNA-anti-miR group compared to the control groups
(p\ 0.0037). The expression of miR-222 was at the lowest
level at 48 h after transfection (Fig. 2).
Expression of miR-222 in B-CLL cell line (183-E95) in
three groups:, scrambled, LNA- anti-mir222 and untreated
determined by quantitative RT-PCR. Numeral upper col-
umns is p value result of compared between groups. Values
shown represent the mean ± SD.
Inhibition of miR-222 Decreased Viabiliy 183-E95
Cells
To assess the effect of miR-222 inhibition on cell viability,
the MTT assay was performed at 24, 48, and 72 h post-
transfection. Cell viability was lower in LNA-anti-miR
group compared to the untreated cells at 48 and 72 h post-
transfection (p\ 0.05). The effect of LNA-anti-miR
transfection on the cell viability increased over time as the
viability of the LNA-anti-miR transfected cell was\47 %
of the untreated cells at 72 h post-transfection. The dif-
ference in the cell viability between the LNA-anti-miR and
both control groups (untreated and scrambled treated) was
statistically significant (p\ 0. 042) at all three intervals
(Fig. 3).
The viability of the untreated cells in each time point
was considered as 100 % and the viability of other groups
is presented as the percentage of the untreated cells in the
same time point. Data were mean ± SD of three inde-
pendent experiments.
Discussion
B-cell chronic lymphocytic leukemia (B-CLL), also known
as chronic lymphoid leukemia (CLL) is a type of cancer of
the white blood cells in adult [5, 23]. CLL has a variable
course, Some patients require little or no treatment, but in
some other patients, the disease is progressive and results
in the death despite various treatments, Effective choices of
treatment are available for CLL patients, including
chemotherapy and monoclonal antibodies [24, 25].These
types of treatments can induce remissions in up to 90 % of
patients. Some patients, however, do not respond to up-
front chemoimmunotherapy combinations, or they develop
resistance to the treatment quickly. Despite recent pro-
gresses in treatment of this disorder, because of the effects
of chemotherapy and radiotherapy, including adverse
effects on normal cells, seeking for new therapies seems
necessary. In the recent years, it has been demonstrated that
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small regulatory non-coding RNAs (ncRNAs) named
microRNAs (miRNAs) are involved in human tumorigen-
esis, Since miRNAs can function as either oncogenes or
tumor suppressor genes in tumorigenesis, the potential of
using these small RNAs as therapeutic targets opens up
new opportunities for cancer treatments by either inhibiting
or augmenting their activity [26].
Among miRNAs significantly deregulated in human
cancer, miR-221/222 are of major interest potential targets
for therapeutic application. miR-221/222 act as oncogenic
miRNAs that as facilitate cell proliferation via down-reg-
ulation of p27KIP1 and/or p57KIP2 [27], as potential targets
for therapeutic applications, which negatively regulate cell
cycle progression from G1- to S-phase [28]. p27 binds to
cyclin-dependent kinase 2 and cyclin E complexes to pre-
vent cell-cycle progression from G1 to S phase. Several
reports suggested a key role of miR-221/222 in tumorige-
nesis. In addition, other authors recently showed that miR-
Fig. 1 Transfection miR-222
show with fluorescent
microscope and flow cytometry
183-E95 cells have been
transfected with 6-FAMTM
fluorescein-conjugated LNA
oligonucleotides and then to
assess transfection efficiency,
they analyzed by flow
cytometry and have been
observed with a fluorescent
microscope. Phase contrast
(a) and fluorescent (b) images
of the same field of 183-E95
cells show that a majority of the
cells were transfected.
Representative FSC-SCS and
FL1-Count flow cytometry
graphs are shown in c. Scale
bars 50 lm
Fig. 2 Evaluation of miR-222 by qRT-PCR performed 24, 48, and
72 h after trasfection
Fig. 3 Evaluation of cell viability by the MTT assay performed 24,
48, and 72 h after transfection
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221/222 antisense oligonucleotides reduce tumor growth
by increasing intra-tumor p27KIP1 protein expression [29].
A evidence suggests that silencing microRNAs with
oncogenic potential may represent a successful therapeutic
strategy for human cancer. A new therapeutic strategy to
inhibit miRNAs that are involved in the pathogenesis of the
disease, which is the aim of the present study, we can use
engineered nucleic acid (LNA) that create a stable con-
nection with the target miRNA and are resistant to nucle-
ases. They particularly disrupt the performance of specific
molecule (miR) which plays a role in prevalence of cancer
[30, 31]. In this study we used LAN-anti-mir to inhibit mir-
222 in B-CLL in cell line 183-E95, Prevention of cellular
proliferation subsequent to the LNA transfection is
indicative of successful inhibition of miR-222 in the cell
line under study. Real time PCR confirmed our data and
miRNAs reduced expression almost by transfection of
LNA. MTT test showed that inhibition of mir-222 caused
reduction of viability cell after 24, 48 and 72 h. Cell via-
bility had the minimal reduction in LNA-scrambled and in
comparison to untreated cells with no significant
difference.
There are many articles related to oncomir that show
treatment with this method is used for many types of
cancers. Inhibition effect of miR-221 by anti-miRNA
oligonucleotide in CLL p53-mutant MEG-01 cells, signif-
icant increase in caspase activity in fludarabine-treated in
cell line [32]. The up expression of miR-221/222 in the
CLL cell line MEC1 promote down-regulation of p27
protein therefore miR-221/222 and p27 may exhibit a
regulatory loop that helps maintaining CLL cells in a
resting condition [20]. The up expression of miR-92a in
APL cell line (HL-60) by LNA antagomir extensively
decreased cell viability [33]. The difference of cell viability
between LNA-anti-miR and control groups was statistically
significant (p\ 0.024). In a study by Di Martino et al. [34]
on the in vitro effect of inhibiting miR-221/222 on cancer
cell multiple myeloma, LNA technology was used to
inhibit miR-221/222. Their studies showed that by
inhibiting miR-221/222 in cell multiple myeloma, p27KIP1,
PUMA and PTEN genes that all have the role of tumor
suppressor in cell cycle are increased but decreased in
reverse cell proliferation. More recently, it has been
reported that the treatment with LNA-modified miR-221
inhibitors reduces the growth of liver cancer cells over-
expressing miR-221/222 in vitro by targeting a DNA
damage-inducible transcript 4 (DDIT4), a modulator of the
mTOR pathway [35].
Chemotherapy is a routine treatment in CLL. But, dif-
ferent findings have been obtained in cases resistant to
treatment. On the other hand, there are some instances that
oncomiR inhibition acts to sensitize the cells to
chemotherapy agents, making this combination therapy
influenced more than any one of the strategies used alone.
Our data suggest that inhibition of miR-222 with LNA-
anti-miR may provide an alternative approach for the
treatment of B-CLL. It can be used alone or in combination
with current therapies to reduce the existing limitations in
the treatment of this malignancy.
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